Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Egcg, a dyrk1a Inhibitor as Therapeutic Tool for Reversing Cognitive Deficits in Down Syndrome Individuals.

This study has been completed.
Sponsor:
Information provided by:
Parc de Salut Mar
ClinicalTrials.gov Identifier:
NCT01394796
First received: July 4, 2011
Last updated: March 12, 2013
Last verified: March 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2011
  Primary Completion Date: February 2011 (Final data collection date for primary outcome measure)